Cure51 Partners with 10x Genomics for Groundbreaking Research
Cure51, a cutting-edge TechBio startup, is embarking on an ambitious initiative aimed at uncovering the complex biology of exceptional cancer survivors. The company plans to analyze over 1,000 tumor samples to harness vital insights that may unlock new therapeutic strategies.
Understanding Exceptional Cancer Survivors
In your life, you may have encountered stories of remarkable individuals who have triumphed over cancer against overwhelming odds. Cure51 seeks to understand what allows these exceptional cancer survivors to defy their prognosis and how their unique biology can illuminate pathways to more effective treatments for all patients.
The Role of Visium HD
To achieve its goals, Cure51 will utilize the Visium HD technology from 10x Genomics. This sophisticated spatial gene expression analysis tool allows researchers to delve deep into the single-cell resolution of tumor samples. By exploring how tumor cells interact with their surrounding microenvironment, researchers hope to uncover the critical factors that contribute to long-term survival.
A Collaborative Approach
Cure51 is working collaboratively with more than 50 oncologic centers around the globe, illustrating the scale and ambition of this initiative. Over the next 18 months, tumor samples will be collected from exceptional cancer survivors residing in 40 different countries. This international collaboration aims to create the first proprietary multi-omics database dedicated to the study of these remarkable individuals.
A Vision for the Future
Nicolas Wolikow and Simon Istolainen, the co-founders of Cure51, express their commitment to changing the narrative around cancer treatments. "At Cure51, we are reverse engineering the cure to cancer by gathering the world’s leading experts and applying advanced technology to unveil the hidden biology of these miraculous survivors," they shared. They believe that their work represents a significant step toward transforming cancer from a life-threatening disease into a manageable condition.
Innovating Cancer Research
Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics, echoes this sentiment, noting the excitement surrounding Cure51's efforts. He explains how pioneering research like this showcases the capabilities of 10x technology to redefine approaches to diagnosing and treating cancer. The aim is to provide tools that can unlock the secrets of survival and potentially lead to a future where cancer care is significantly improved.
As Cure51 continues its journey in cancer research, the partnership with 10x Genomics is pivotal. The insights gained from this work could pave the way for breakthroughs in drug discovery, offering hope to countless individuals battling cancer.
Contact Details
For further inquiries, please reach out to Clara Armand-Delille, who can provide additional information about Cure51's initiatives and future plans.
Frequently Asked Questions
What is Cure51’s main focus?
Cure51 focuses on studying exceptional cancer survivors to unlock insights that can lead to innovative cancer therapies.
How many tumor samples will Cure51 analyze?
The initiative aims to analyze over 1,000 tumor samples from exceptional cancer survivors.
What technology is Cure51 using for its research?
Cure51 is utilizing the Visium HD technology from 10x Genomics for spatial gene expression analysis.
How many oncologic centers are involved in the research?
More than 50 oncologic centers are collaborating with Cure51 for this international initiative.
What do the founders of Cure51 believe about the future of cancer treatment?
The founders believe that cancer can become a manageable disease and are dedicated to developing technology that can help achieve this vision.
